Johnson & Johnson: human testing of its coronavirus vaccine to begin by September
Johnson & Johnson announced human testing of its experimental vaccine for the coronavirus will begin by September and it could be available for emergency use authorization in early 2021.
J&J also said it has committed more than $1 billion of investment in partnership with the federal Biomedical Advanced Research and Development Authority, which is part of the Department of Health and Human Services, to co-fund vaccine research.
J&J’s lead vaccine candidate will enter a phase 1 human clinical study by September, the company said, and clinical data on its effects is expected before the end of the year. If the vaccine works well, the company said it could be available for emergency use in early 2021.
CNBC
Related news
HPAI vaccine bank at the service of epidemic prevention
The National Food Chain Safety Office established an HPAI vaccine…
Read more >MÁOK and Nébih warn about the importance of protection against rabies
Since the beginning of the year, investigations by the National…
Read more >Inaugurated Nébih’s new animal house and high security research laboratory
Dr. Márton Nobilis, Secretary of State for Food and Trade…
Read more >Related news
The Night of Modern Factories event series is becoming more and more successful
The national online and live event series The Night of…
Read more >The new competitiveness-enhancing EU tenders were presented at the information forum of the Budapest Chamber amid huge entrepreneurial interest.
After a gap of more than a decade, EU tenders…
Read more >The most exciting agricultural technology event is coming
The rebirth of agriculture in the struggles of the generations,…
Read more >